Home › NDC Lookup › RxCUI directory › RxCUI 2742555

Calcipotriene 0.05 MG/ML Topical Solution [Pellix] — RxCUI 2742555

RxNorm drug concept · Semantic branded drug
RxCUI 2742555 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2742555
Official nameCalcipotriene 0.05 MG/ML Topical Solution [Pellix]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asPellix 0.005 % Topical Solution; Pellix 0.05 MG/ML Topical Solution
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Calcipotriene Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Calcipotriene is not a steroid at all — it's a synthetic form of vitamin D3. While steroid creams work by suppressing inflammation, calcipotriene is thought to work by binding to v...
  • What exactly is calcipotriene, and how is it different from a steroid cream?
  • No — calcipotriene should not be applied to the face. The label is clear on this for all product forms. If you have psoriasis on your face, talk to your dermatologist about other o...
  • Can I use this on my face if my psoriasis is there too?
📖 Read our full Calcipotriene Topical guide →

🕸️ Concept Web — How Calcipotriene 0.05 MG/ML Topical Solution [Pelli... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Calcipotriene 0.05 MG/ML Topical Solution [Pellix] RxCUI 2742555

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Calcipotriene 29365
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Pellix 2742551
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Calcipotriene Topical Solution 371186
    • Calcipotriene Topical Product 1164954
    • Calcipotriene Topical Solution [Pellix] 2742554
    • Pellix Topical Product 2742553
    • Topical Solution 316986
    • Topical Product 1151122
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Calcipotriene 0.05 MG/ML [Pellix] SBDC · 2742552
  • Calcipotriene Topical Solution [Pellix] SBDF · 2742554
  • Pellix Topical Product SBDG · 2742553
  • Pellix BN · 2742551

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2742555 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
87143-0300-60 1 BOTTLE, PLASTIC in 1 CARTON (87143-300-60) / 60 mL in 1 B... Pellix Perfero Pharma, Inc. 2026-05-04
Observed labelers: Perfero Pharma, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.